Rattle Snake Envenomation Follow-up

  • Author: Sean P Bush, MD, FACEP; Chief Editor: Rick Kulkarni, MD   more...
 
Updated: Nov 2, 2010
 

Further Inpatient Care

All patients with rattlesnake envenomation should be admitted to the hospital and remain there while undergoing treatment with antivenom. Close observation and frequent measurements of swelling (every 1-2 h) for approximately 24 hours after initial control is recommended.

Patients who are believed to have a dry bite in which no venom effects develop should be observed for at least 8 hours. A close follow-up and/or recheck examination is recommended.

Several reports in the literature have documented instances in which patients who were initially discharged with a mild envenomation returned in several hours with significant injury and required antivenom and admission.[28]

Next

Further Outpatient Care

Discharge instructions should include the following:

  • Return immediately if swelling worsens or pain becomes severe.
  • Return immediately if any abnormal bleeding or bruising, petechiae, dark tarry stools, or severe headache occur.
  • Return for signs of wound infection, such as swelling, excessive tenderness, redness or streaks, heat, or drainage (pus).[29]
  • Return or follow up if a fever, itchy rash, joint pain, or swollen lymph nodes occur any time during the next few weeks.
  • Do not take nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin, Advil), or naproxen (Naprosyn, Aleve) for 2 weeks after the snakebite. Acetaminophen (Tylenol) or a prescribed pain medication can be taken.
  • Do not participate in contact sports, undergo elective surgery, or have dental work for 2 weeks after the snakebite.
  • Drink plenty of liquids. Return if urine decreases in amount or becomes cola colored.
  • Referral to a physical therapist or surgeon may be indicated. If bitten on the foot or leg, crutches and crutch training should be provided. Elevate and mobilize affected extremity as tolerated.
  • Next day wound check should be performed at the physician's discretion on a case-by-case basis. The patient should return to the ED or follow up every 3 days for 2 weeks with repeat CBC, PT/INR, and fibrinogen. Laboratory results may need to be rechecked more or less frequently or for a longer or shorter duration on a case-by-case basis.
Previous
Next

Inpatient & Outpatient Medications

Administer antihistamines if serum sickness develops. Steroids may be indicated for more severe cases of serum sickness.

Previous
Next

Transfer

All hospitals should have enough antivenom to treat at least one patient. However, antidote stocking varies and shortages do occur. Therefore, if antivenom is not available at the presenting hospital, the patient should be transferred to a facility where antivenom may be administered. However, if it is available, antivenom may be necessary to optimize stabilization of a patient prior to transfer.

Previous
Next

Deterrence/Prevention

Never handle a rattlesnake, even if it is believed to be dead. Serious, even fatal, envenomations have been documented to occur after handling the decapitated head of a rattlesnake up to 90 minutes after it was severed.

  • Do not reach or step into places outdoors that are not visible.
  • At home, remove debris in which snakes might hide (eg, log piles). Remove items, such as bird feeders, that might attract snakes—seeds that fall from bird feeders attract rodents, which attract snakes.
  • Heavy clothing (such as hiking boots) may retard some strikes.
  • Young children should be closely supervised, and older children should be educated to avoid snakes in indigenous areas.
  • Keep the garage door closed to prevent rattlesnakes from seeking shelter in the garage.
  • Many cases of envenomation involve alcohol. Do not use alcohol and place oneself in an environment that may be shared with rattlesnakes or play with snakes while intoxicated.
Previous
Next

Complications

Complications of snake envenomation may include the following:

  • Bleeding, such as gastrointestinal or intracranial
  • Compartment syndrome
  • Necrosis with resulting tissue loss or loss of function
  • Rhabdomyolysis, myoglobinuric renal failure
  • Infection
  • Respiratory difficulty
  • Death (rare in the United States)
  • Antivenom-associated complications
    • Anaphylaxis is a type I (immediate) hypersensitivity reaction, which may be life threatening. It is characterized by urticaria, airway swelling, wheezing, and shock. Some degree of anaphylaxis may occur in as many as 25% of patients given Antivenin (Crotalidae) Polyvalent. Risk factors include previous exposure to horse serum or antivenom or a history of reactive airways. Immediate hypersensitivity is treated with epinephrine, antihistamines, steroids, and ventilatory/circulatory support, as needed. Although experience is limited, immediate hypersensitivity is less common after treatment with CroFab.
    • Serum sickness is a type III (delayed) hypersensitivity reaction. It is characterized by fever, urticaria, lymphadenopathy, and arthritis and may occur 3 days to 3 weeks after Antivenin (Crotalidae) Polyvalent administration in as many as 50% of patients. Serum sickness is dose-related; it almost always occurs when more than 8 vials of Antivenin (Crotalidae) Polyvalent are administered. Although serum sickness can be uncomfortable, it is usually benign and self-limited and is treated with steroids and antihistamines. Delayed hypersensitivity is much less common after treatment with CroFab, although experience with this relatively new medication is limited.
Previous
Next

Prognosis

Before antivenom, estimates of mortality rates ranged from 5-25%.

Since the development of antivenom, rapid EMS transport, and emergency/intensive care, mortality rates have improved to less than 0.28% when antivenom is administered and to 2.6% when antivenom is not administered.

Less specific figures are available for morbidity data, although most patients recover fully after rattlesnake envenomation. The best estimates suggest that rattlesnake envenomation results in tissue loss, deformity, or loss of function in approximately 10% of patients.

Previous
Next

Patient Education

Call professionals, such as animal control, to move snakes (if it is necessary to move the snake).

Never attempt to handle, possess, or kill venomous reptiles.

For patient education resources, visit eMedicine's Bites and Stings Center. Also, see eMedicine's patient education article Snakebite.

Previous
 
Contributor Information and Disclosures
Author

Sean P Bush, MD, FACEP  Professor of Emergency Medicine, Loma Linda University School of Medicine; Consulting Staff, Envenomation Specialist, Department of Emergency Medicine, Loma Linda University Medical Center

Sean P Bush, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, International Society on Toxicology, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Protherics Consulting fee Consulting; Nycomed (formerly Fougera) Grant/research funds Speaking and teaching; Rare Disease Therapeutics Grant/research funds Research; Bioclon Grant/research funds Research

Specialty Editor Board

Robert L Norris, MD  Professor, Department of Surgery, Chief, Division of Emergency Medicine, Stanford University Medical Center

Robert L Norris, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, California Medical Association, International Society of Toxinology, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD  Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

James Steven Walker, DO, MS  Clinical Professor of Surgery, Department of Surgery, University of Oklahoma College of Medicine

James Steven Walker, DO, MS is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Osteopathic Emergency Physicians, and American Osteopathic Association

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD  Attending Physician, Department of Emergency Medicine, Cambridge Health Alliance, Division of Emergency Medicine, Harvard Medical School

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

References
  1. Watson WA, Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, Youniss J, Reid N, et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 2004;22(5):335-404. [Medline].

  2. Bronstein AC, Spyker DA, Cantilena LR Jr, Green J, Rumack BH, Heard SE. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila). Dec 2007;45(8):815-917. [Medline].

  3. Wingert WA, Chan L. Rattlesnake bites in southern California and rationale for recommended treatment. West J Med. Jan 1988;148(1):37-44. [Medline].

  4. Langley RL, Morrow WE. Deaths resulting from animal attacks in the United States. Wilderness Environ Med. 1997;8:8-16.

  5. Norris RL Jr. Snake Venom Poisoning in the United States: Assessment and Management. Emerg Med Rep. 1995;16:87-94.

  6. Norris Jr RL, Bush SP. North American venomous reptile bites. In: Auerbach PS, ed. Wilderness Medicine. 5th ed. 2006.

  7. Bush SP, Jansen PW. Severe rattlesnake envenomation with anaphylaxis and rhabdomyolysis. Ann Emerg Med. Jun 1995;25(6):845-8. [Medline].

  8. Bond RG, Burkhart KK. Thrombocytopenia following timber rattlesnake envenomation. Ann Emerg Med. Jul 1997;30(1):40-4. [Medline].

  9. Hurlbut KM, Dart RC, et al. Reliability of clinical presentation for predicting significant pit viper envenomation. Ann Emerg Med. 1988;438-9.

  10. Bogdan GM, Dart RC. Prolonged and recurrent coagulopathy after North American pit viper envenomation (abstract). Ann Emerg Med. 1996;27:820.

  11. Boyer LV, Seifert SA, Clark RF, McNally JT, Williams SR, Nordt SP, et al. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med. Apr 12 1999;159(7):706-10. [Medline].

  12. Burgess JL, Dart RC. Snake venom coagulopathy: use and abuse of blood products in the treatment of pit viper envenomation. Ann Emerg Med. Jul 1991;20(7):795-801. [Medline].

  13. Riffer E, Curry SC, Gerkin R. Successful treatment with antivenin of marked thrombocytopenia without significant coagulopathy following rattlesnake bite. Ann Emerg Med. Nov 1987;16(11):1297-9. [Medline].

  14. Carroll RR, Hall EL, Kitchens CS. Canebrake rattlesnake envenomation. Ann Emerg Med. Jul 1997;30(1):45-8. [Medline].

  15. French WJ, Hayes WK, Bush SP, Cardwell MD, Bader JO, Rael ED. Mojave toxin in venom of Crotalus helleri (Southern Pacific Rattlesnake): molecular and geographic characterization. Toxicon. Dec 1 2004;44(7):781-91. [Medline].

  16. Spaite D, Dart R, Sullivan JB. Skin testing in cases of possible crotalid envenomation. Ann Emerg Med. Jan 1988;17(1):105-6. [Medline].

  17. Bush SP. Snakebite suction devices don't remove venom: they just suck. Ann Emerg Med. Feb 2004;43(2):187-8. [Medline].

  18. Bush SP, Hegewald KG, Green SM, Cardwell MD, Hayes WK. Effects of a negative pressure venom extraction device (Extractor) on local tissue injury after artificial rattlesnake envenomation in a porcine model. Wilderness Environ Med. Fall 2000;11(3):180-8. [Medline].

  19. Bush SP, Green SM, Laack TA, Hayes WK, Cardwell MD, Tanen DA. Pressure immobilization delays mortality and increases intracompartmental pressure after artificial intramuscular rattlesnake envenomation in a porcine model. Ann Emerg Med. Dec 2004;44(6):599-604. [Medline].

  20. Hardy DL, Bush SP. Pressure/immobilization as first aid for venomous snakebite in the United States. Herpetol Rev. 1998;29:204-8.

  21. Consroe P, Egen NB, Russell FE, Gerrish K, Smith DC, Sidki A, et al. Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice. Am J Trop Med Hyg. Nov 1995;53(5):507-10. [Medline].

  22. Bush SP, Wu VH, Corbett SW. Rattlesnake venom-induced thrombocytopenia response to Antivenin (Crotalidae) Polyvalent: a case series. Acad Emerg Med. Feb 2000;7(2):181-5. [Medline].

  23. Bush SP, Green SM, Moynihan JA, Hayes WK, Cardwell MD. Crotalidae polyvalent immune Fab (ovine) antivenom is efficacious for envenomations by Southern Pacific rattlesnakes (Crotalus helleri). Ann Emerg Med. Dec 2002;40(6):619-24. [Medline].

  24. Dart RC, Seifert SA, Carroll L, Clark RF, Hall E, Boyer-Hassen LV, et al. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning. Ann Emerg Med. Jul 1997;30(1):33-9. [Medline].

  25. Jurkovich GJ, Luterman A, McCullar K, Ramenofsky ML, Curreri PW. Complications of Crotalidae antivenin therapy. J Trauma. Jul 1988;28(7):1032-7. [Medline].

  26. Offerman SR, Bush SP, Moynihan JA, Clark RF. Crotaline Fab antivenom for the treatment of children with rattlesnake envenomation. Pediatrics. Nov 2002;110(5):968-71. [Medline].

  27. Premawardhena AP, de Silva CE, Fonseka MM, Gunatilake SB, de Silva HJ. Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomised, placebo controlled trial. BMJ. Apr 17 1999;318(7190):1041-3. [Medline].

  28. Guisto JA. Severe toxicity from crotalid envenomation after early resolution of symptoms. Ann Emerg Med. Sep 1995;26(3):387-9. [Medline].

  29. Clark RF, Selden BS, Furbee B. The incidence of wound infection following crotalid envenomation. J Emerg Med. Sep-Oct 1993;11(5):583-6. [Medline].

Previous
Next
 
Juvenile southern Pacific rattlesnake (Crotalus oreganus helleri). Photo by Sean Bush, MD.
A recent study suggests that the Extractor (Sawyer Products) does not reduce swelling after rattlesnake envenomation and may be associated with skin necrosis beneath the suction cup. Photo by Sean Bush, MD.
Moderate rattlesnake envenomation in a toddler after treatment with antivenom. Photo by Sean Bush, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.